Denali Therapeutics (NASDAQ:DNLI) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $90.00 price objective on the stock.

A number of other brokerages also recently commented on DNLI. Citigroup boosted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a buy rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their price target on Denali Therapeutics from $28.00 to $29.00 and gave the company an overweight rating in a report on Wednesday, July 10th. Wedbush cut their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an outperform rating on the stock in a report on Friday, August 2nd. Finally, Stifel Nicolaus lowered their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a hold rating for the company in a report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $38.30.

Denali Therapeutics Trading Up 0.2 %

DNLI traded up $0.04 on Wednesday, hitting $25.16. 702,013 shares of the company were exchanged, compared to its average volume of 1,134,894. The firm has a 50-day moving average price of $23.18 and a two-hundred day moving average price of $20.68. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $25.90. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -26.21 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to analysts' expectations of $10.00 million. During the same quarter in the previous year, the company posted $1.30 earnings per share. The firm's quarterly revenue was down 99.7% on a year-over-year basis. Equities analysts expect that Denali Therapeutics will post -2.54 EPS for the current year.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $22.12, for a total transaction of $663,600.00. Following the completion of the transaction, the director now directly owns 34,404 shares of the company's stock, valued at $761,016.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Steve E. Krognes sold 30,000 shares of the company's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the transaction, the director now owns 34,404 shares of the company's stock, valued at $761,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jennifer E. Cook sold 1,458 shares of the firm's stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares of the company's stock, valued at approximately $435,425.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,146 shares of company stock worth $710,274. Company insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. EP Wealth Advisors LLC purchased a new stake in shares of Denali Therapeutics in the first quarter valued at about $831,000. Edmond DE Rothschild Holding S.A. grew its holdings in Denali Therapeutics by 65.9% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 165,680 shares of the company's stock valued at $3,555,000 after buying an additional 65,800 shares during the last quarter. Pathway Capital Management LP purchased a new position in Denali Therapeutics during the fourth quarter worth $1,490,000. Edgestream Partners L.P. acquired a new position in shares of Denali Therapeutics in the first quarter worth $2,301,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Denali Therapeutics in the first quarter valued at $4,330,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.